Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

INDUSTRY 2NETWORK 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Thoracic 3

Conditions

Carcinoma, Non-Small-Cell Lung 3Lung Neoplasms 2Adenocarcinoma of Lung 1

Interventions

pembrolizumab 59Carboplatin 56Pemetrexed 47Cisplatin 39Paclitaxel 24Nivolumab 23Docetaxel 21durvalumab 20Gemcitabine 15130-nm albumin-bound paclitaxel 14osimertinib 13Cetuximab 12Specimen Handling 11Magnetic Resonance Spectroscopy 11atezolizumab 10amivantamab 8Taxes 8Radiotherapy 8Radiosurgery 7Ipilimumab 7lazertinib 6alectinib 6Ramucirumab 6Observation 6Bevacizumab 6cemiplimab 5Leucovorin 5Fluorouracil 5Etoposide 5Erlotinib Hydrochloride 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Carcinoma, Non-Small-Cell Lung × capmatinib × 30 days × Clear all
NCT05488314 2026-06-05

METalmark

Janssen Research & Development, LLC

Phase 1/2 Active not recruiting
57 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05642572 2026-06-03

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

SWOG Cancer Research Network

Phase 2 Recruiting
66 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05703516 2026-06-01

A Post Approval Commitment Study on Tabrecta® (Capmatinib) in South Korea

Novartis

Recruiting
44 enrolled
Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡